Jean J. Kiladjian

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.

Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.

Journal: Blood

Published: December 09, 2024

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients.

Journal: Cancer medicine

Published: December 27, 2018

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.

Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis.

Journal: Blood

Published: November 15, 2018

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Journal: Blood cancer journal

Published: July 09, 2018

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia.

Journal: Leukemia research

Published: April 18, 2018

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project.

Journal: Haematologica

Published: April 07, 2018

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Journal: The New England journal of medicine

Published: January 29, 2015

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts.

Journal: Blood

Published: January 21, 2014

Treatment target in polycythemia vera.

Treatment target in polycythemia vera.

Journal: The New England journal of medicine

Published: April 19, 2013

Showing 1-9 of 9

Last Updated: 09/26/2026